Flask stand, Suitable for, Flask 10 ml, 3 Piece(s)

Olmesartan, 98%, 500mg

N-(4-Formylpyridin-3-yl)-2,2-dimethyl-propionamide, 95+%, 5g

6-chloro-3-(methoxymethyl)[1,2,4]triazolo[4,3-b]pyridazine, 95.0%, 250mg

E-Plan phase EPLPHi 20x/0.40 infinity corrected IOS objective. Working distance 2.61 mm

1,4-PIPERIDINEDICARBOXYLIC ACID, 4-[[(1,1-DIMETHYLETHOXY)CARBONYL]AMINO]-, 4-METHYL 1-(PHENYLMETHYL) ESTER, 95.0%, 100mg

2-Amino-3-hydroxypropanenitrile hydrochloride, 98%, 250mg

4-{2,4-Dioxo-3-azatricyclo[7.3.1.0,5,13]trideca-1(13),5,7,9,11-pentaen-3-yl}butanoic acid, 98+%, 100mg

Lithium 9-(((E)-4-((2S,3R,4R,5S)-3,4-dihydroxy-5-(((2S,3S)-3-((2S,3S)-3-hydroxybutan-2-yl)oxiran-2-yl)methyl)tetrahydro-2H-pyran-2-yl)-3-methylbut-2-enoyl)oxy)nonanoate, 95%, 1g

1-[(6-nitro-1,3-benzothiazol-2-yl)thio]acetone, 95.0%, 5g

1-Iodo-2-methylbutane (stabilized with Copper chip)>95.0%(GC)25g

O-(tert-Butyl)hydroxylamine Hydrochloride>98.0%(N)(T)1g

4-Bromo-2-(difluoromethoxy)benzoic acid, 95%, 1g